Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Immunology
Facteur d'impact: 1.352 Facteur d'impact sur 5 ans: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimer: 1040-8401
ISSN En ligne: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.90
13 pages

Dendritic Cells in Cancer Immunotherapy

Matthias Gunzer
Department of Dermatology, University of Munster, Germany
Stephan Grabbe
Department of Dermatology, University of Munster, Germany

RÉSUMÉ

Antigen presentation is a critical regulatory element for the induction of cellular immune responses. Thus, one of the principal current goals of tumor immunotherapy is to control and enhance tumor antigen presentation. In this respect, dendritic cells (DC) are now being widely investigated as immunotherapeutic agents for the treatment of disseminated malignancies. At present, numerous ways to employ DCs for tumor immunotherapy are being tested, ranging from direct in situ expansion and activation of DCs to adoptive transfer of ex vivo generated DCs, and numerous techniques have been designed to optimize DC activation, tumor antigen delivery to DCs, and induction of tumor-specific, as well as helper immune responses, in vivo. However, the results of recent preclinical studies and the diversity of the clinical phase I trials that are currently underway indicate that little is still known about the exact mechanisms by which DCs modulate tumor immunity and pose the concern that premature clinical trials might not yield the desired results and might be harmful to, rather than promote, the concept of DC-based tumor immunotherapy. This review summarizes some of the current approaches to induce tumor immunity by DC-based vaccination and discusses their advantages and concerns.


Articles with similar content:

Current Vaccination Strategies for the Treatment of B-Cell Lymphoma and Multiple Myeloma
Critical Reviews™ in Immunology, Vol.29, 2009, issue 5
Nurit Hollander
Dendritic Cell-Based Vaccines: From Mouse Models to Clinical Cancer Immunotherapy
Critical Reviews™ in Oncogenesis, Vol.11, 2000, issue 1
Carl G. Figdor, Gosse J. Adema, Marco W. J. Schreurs, Andreas A. O. Eggert, Cornells J. A. Punt
Tumor Antigen Presentation by Dendritic Cells
Critical Reviews™ in Immunology, Vol.30, 2010, issue 4
Nina Dickgreber, Ian F. Hermans, Troels R. Petersen
Acquisition and Presentation of Tumor Antigens by Dendritic Cells
Critical Reviews™ in Immunology, Vol.35, 2015, issue 5
Guido Ferlazzo, Stefania Campana, Irene Bonaccorsi, Barbara Morandi
The Phenotype and Function of Lung Dendritic Cells
Critical Reviews™ in Immunology, Vol.25, 2005, issue 6
Allison T. Thiele, Kena A. Swanson, Tina L. Sumpter, Tonya J. Webb, David S. Wilkes